Simon Chun Ho Yu MD, Abstract Co-Author: Nothing to Disclose

Judy Suk-yee Lam MBBCh, Presenter: Nothing to Disclose

Joyce Wai Yee Hui, Abstract Co-Author: Nothing to Disclose

Edwin P. Hui, Abstract Co-Author: Nothing to Disclose

John Wong, Abstract Co-Author: Nothing to Disclose

Herman Wong, Abstract Co-Author: Nothing to Disclose

Frankie Mo, Abstract Co-Author: Nothing to Disclose

Simon Sze Ming Ho MBBS, Abstract Co-Author: Nothing to Disclose

Yuen Yee Wong, Abstract Co-Author: Nothing to Disclose

Winnie Yeo, Abstract Co-Author: Nothing to Disclose

Paul Lai, Abstract Co-Author: Nothing to Disclose

Anthony Chan, Abstract Co-Author: Nothing to Disclose

Tony Mok, Abstract Co-Author: Nothing to Disclose

et al, Abstract Co-Author: Nothing to Disclose

et al, Abstract Co-Author: Nothing to Disclose

This prospective trial aims to evaluate the safety and efficacy of transarterial ethanol ablation of intrahepatic lesions of hepatocellular carcinoma (HCC) with Lipiodol-ethanol mixture (LEM).

Seventy-seven patients (60 men, 17 women, average age 63.4±11.3 years) were recruited and 164 intrahepatic lesions of HCC treated. The average size of the largest tumor lesion at enrollment was 5.2±3.0cm, ranged 1.5cm to 15cm. LEM consisted of 33% of ethanol by volume. Adverse events and laboratory test results were observed. Tumor response was evaluated with CT scan and serum alphafetoprotein (AFP) level. Patient survival was estimated with the method of Kaplan-Meier.

The average number of treatments for each patient was 2.3±1.4 sessions. Acute hepatic decompensation and irreversible hepatic decompensation occurred in 9.9% and 0.6% of the procedures respectively. Complete ablation and near-complete ablation were noted in 86% and 12.8% of the 164 treated lesions respectively. Complete ablation by radiological criteria was achieved in 61 patients (79.2%). The median overall survival time was 2.2 years. Patient survival rate and progression free survival rate at 1 year, 2 years were 77.9%, 50.1% and 63.6%, 46.3% respectively.

Transarterial ethanol ablation is a safe and effective means for local control of intrahepatic HCC.

Transarterial ethanol ablation is a safe and effective means for local control of intrahepatic HCC.

Yu, S, Lam, J, Hui, J, Hui, E, Wong, J, Wong, H, Mo, F, Ho, S, Wong, Y, Yeo, W, Lai, P, Chan, A, Mok, T, et al, , et al, , A Phase 2 Prospective Clinical Trial of Transarterial Ethanol Ablation for Hepatocellular Carcinoma.  Radiological Society of North America 2007 Scientific Assembly and Annual Meeting, November 25 - November 30, 2007 ,Chicago IL. http://archive.rsna.org/2007/5006646.html